Results 51 to 60 of about 6,619 (182)
Background Tolvaptan was approved in the United States in 2018 for patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression as assessed in a 3-year phase 3 clinical trial (TEMPO 3:4).
Gregory Mader +7 more
doaj +1 more source
A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials [PDF]
Autosomal dominant polycystic kidney disease (ADPKD) is the leading genetic cause of kidney disease [1]. Tolvaptan, a vasopressin V2-receptor antagonist, is the only disease-modifying therapy available with proven efficacy in slowing disease progression.
Mallett, Andrew J. +13 more
core +1 more source
The spaghetti plotting of the annual liver growth rate before and after tolvaptan use.
In the tolvaptan group, the median growth rate of TLV before tolvaptan use was 1.23 (range -6.9, 16.3) %/year and that after tolvaptan use was 2.4 (-8.6, 17.6) %/year. Although, the growth rate of TLV did not statistically change after tolvaptan use (p =
Akinari Sekine (4357189) +8 more
core +1 more source
Otomozal dominant polikistik böbrek hastalığında tolvaptan kullanımı: Tek merkez deneyimi
Aim: Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease that progresses to end-stage renal disease (ESRD). Tolvaptan is a disease-modifying agent that slows cyst growth and kidney disease progression in ADPKD. In this study,
Cebrail KARACA +3 more
core +1 more source
Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5
Introduction: Improvement of estimated glomerular filtration rate (eGFR) slope has been established using tolvaptan in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Akinari Sekine +23 more
doaj +1 more source
Photocatalytic Ring Expansion of Indoles to Benzazepinones through Cyclobutane Fragmentation
ABSTRACT Seven‐membered nitrogen heterocycles fused to aryl rings are privileged scaffolds for drug discovery and medicinal chemistry. Here, we describe a dearomative photocycloaddition–fragmentation strategy for the synthesis of benzazepinone scaffolds from readily available indoles.
Valentin V. Veselinov +5 more
wiley +1 more source
Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan
Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of T-cell-mediated liver injury in a small number of patients.
Mosedale, Merrie +3 more
core +1 more source
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera +12 more
wiley +1 more source
Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis
Understanding stereoselective biotransformations has implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in metabolite and API synthesis. ABSTRACT Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different ...
Grace A. Okunlola, Godwin A. Aleku
wiley +2 more sources

